1140496-05-4

Basic information

• Product Name: (S)-7-(Trifluoromethyl)chroman-4-amine
• Synonyms: (S)-7-(Trifluoromethyl)chroman-4-amine
• CAS NO: 1140496-05-4
• Molecular Formula: C₁₀H₁₀F₃NO
• Molecular Weight: 217.1877096
• Mol File: 1140496-05-4.mol

Chemical Properties

• Boiling Point: 249.656 °C at 760 mmHg
• Flash Point: 104.789 °C
• Appearance: /
• Density: 1.29 g/cm³
• Storage Temp.: 2-8°C
• PKA: 8.27±0.20(Predicted)
• CAS DataBase Reference: (S)-7-(Trifluoromethyl)chroman-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-7-(Trifluoromethyl)chroman-4-amine(1140496-05-4)
• EPA Substance Registry System: (S)-7-(Trifluoromethyl)chroman-4-amine(1140496-05-4)

Safety Data

• Hazardous Substances Data: 1140496-05-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(S)-7-(Trifluoromethyl)chroman-4-amine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and the presence of a trifluoromethyl group contribute to its potential as a building block for other organic molecules, enhancing the development of novel therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-7-(Trifluoromethyl)chroman-4-amine serves as a valuable compound for the design and optimization of new drugs. Its chiral nature and the trifluoromethyl group can be leveraged to modulate the compound's pharmacokinetic and pharmacodynamic properties, leading to improved drug efficacy and selectivity.
Used in Chemical Synthesis:
(S)-7-(Trifluoromethyl)chroman-4-amine is employed as a versatile building block in organic synthesis. Its unique structure allows for further functionalization and modification, enabling the creation of a wide range of chemical entities with diverse applications.
Further studies are required to fully explore the potential uses and properties of (S)-7-(Trifluoromethyl)chroman-4-amine, as its unique structure and the presence of a trifluoromethyl group offer promising avenues for pharmaceutical research, drug development, and chemical synthesis.

Upstream product

• 111141-02-7 2,3-dihydro-7-(trifluoromethyl)-4H-1-benzopyran-4-one 
• 704208-25-3 7-Trifluoromethyl-chroman-4-ylamine 
• 6290-49-9 methyl methoxyacetate 
• 890838-99-0 7-trifluoromethyl-chroman-4-one O-methyl-oxime 

Downstream Products

• 1140496-24-7 (3R,5R)-1-(((S)-7-(trifluoromethyl)chroman-4-yl)carbamoyl)-5-(4-(4-chlorobenzyl)-5-methyl-4H-1,2,4-triazol-3-yl)pyrrolidin-3-yl acetate 
• 1140492-27-8 (R)-2-(4-((S)-1-(4-chlorophenyl)ethyl)-5-methyl-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl)pyrrolidine-1-carboxamide 
• 1140488-92-1 (R)-2-(4-(4-chlorobenzyl)-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140489-55-9 (R)-2-(4-(4-chlorobenzyl)-5-methyl-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140490-73-8 (R)-2-(4-(4-chlorobenzyl)-5-ethyl-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140490-58-9 (R)-2-(4-(4-chlorobenzyl)-5-chloro-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140491-04-8 (R)-2-(4-(4-chlorobenzyl)-5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140488-95-4 (R)-2-(2-(4-Chlorobenzyl)-2H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)chroman-4-yl)pyrrolidine-1-carboxamide 
• 1140489-41-3 (R)-2-(2-(4-chlorobenzyl)-5-methyl-2H-1,2,4-triazol-3-yl)-N-((S)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-yl)pyrrolidine-1-carboxamide 

Relevant articles and documents

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES and INFLAMMATION

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.